Ruth Wangondu MD PhD

Physician Scientist Instructor @stjuderesearch. 2020-23 ASH Minority Hematology Fellow Award Recipient #ASH22. Views my own. Retweets not endorsements.

[Ruth Wangondu MD PhD @Wang_Rwang]

I’m honored to be a 2026 St. Baldrick’s Scholar. Thank you, @StBaldricks! This award will support our work to uncover how the IKZF1 N159Y mutation drives pediatric leukemia and to identify new therapeutic strategies for children with B-ALL. @StJudeResearch

[St. Baldrick's Foundation @StBaldricks]

$10.3 million. 28 research projects. 1 shared goal: Conquer Kids' Cancer.

Because of you, we're investing in the brightest minds in pediatric cancer research & helping bring new hope to kids and families everywhere.

See what your support makes possible: https://t.co/P7RuJSzIFW

[Ruth Wangondu MD PhD @Wang_Rwang]

@StBaldricks Thank you, @StBaldricks! I’m honored to be a 2026 St. Baldrick’s Scholar. This award will support our work to uncover how the newly discovered IKZF1 N159Y mutation drives pediatric leukemia and to identify new therapeutic strategies for children with B-ALL. Grateful!

[Brendon Stiles @BrendonStilesMD]

Proud to share our latest work from @MontefioreNYC @EinsteinMed examining molecular testing in early-stage lung adeno. Comprehensive NGS revealed important differences in EGFR & KRAS subtypes in our diverse patient population, reinforcing why equitable testing and trials matter.

[Ruth Wangondu MD PhD @Wang_Rwang]

No Data ZoneHope on Hold: Novel Drug Access Out of Reach for Children With Acute Myeloid Leukemia Despite Adult Successes https://t.co/ftVG76bc5p

[Shicheng Guo @ShihchengGuo]

KidneyGenAfrica GWAS meta-analysis on 110k Africans reveals 4 significant loci affecting kidney function, including 2 novel ones, from 26k in Africa, 81k diaspora. PMID:41667462, Nat Commun 2026, @NatureComms https://t.co/S7IgMorS8p #AI #Pharma #BioMed #RNA #ASHG #ESHG

[Ruth Wangondu MD PhD @Wang_Rwang]

This year, the American Society of Hematology committed over $20M to protect hematology research and keep scientists’ life-saving work moving forward. Join the #Fight4Hematology with a gift to the ASH Foundation. https://t.co/KmTnVxzw3j

[ALL Hub @ALL_Hub_]

CONGRESS | #ASH25 | PRESENTATION
Ruth Wang'ondu shares findings from the Children's Oncology Group studies AALL0932 and AALL1131 evaluating outcomes in children with NCI standard-risk (SR) B-ALL stratified as high-risk (HR) or very high-risk (VHR) treated with intensified post-induction therapy.
After 3-drug chemotherapy and augmented BFM chemotherapy; patients with favorable cytogenetics or EOI MRD ≥ 0.01% or with neutral cytogenetics and EOI MRD < 0.01%, and CNS-1/2, had favorable outcomes (SR->HR) and poor responders can be rescued. Patients with unfavourable cytogenetics or induction failure or with neutral cytogenetics and EOI MRD ≥ 0.01%, and CNS-1/2, had favorable outcomes (SR->VHR) and poor responders can be rescued.
Follow our live feed for more updates: https://t.co/KrqKaCrky0
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#ALLsm #leusm #MedicalCongress #MedEd #MedNews @Wang_Rwang @StJudeResearch

[Ruth Wangondu MD PhD @Wang_Rwang]

@ALL_Hub_ It was indeed an honor and privilege to present these outcomes of two major children’s oncology group trials at #ASH2025. Outcomes with 3-drug induction are very good to excellent for 25% of NCI SR B-ALL who are high or very-high risk.

[Talha Badar @TalhaBadarMD]

Clonal hematopoiesis landscape in frequent blood donors https://t.co/lkThd0bRe3

Frequent blood donor &gt; 120 lifetime donations; led to EPO driven HSCs carrying DNMT3A mutations!
#CH #clonal_hematopoiesis

[Ruth Wangondu MD PhD @Wang_Rwang]

@Mr_Guantai In the interests of safeguarding the public’s health, the veracity of these claims ought to be investigated by media and legislators, as a matter of priority. @mdjkitulu @KTNNewsKE

[Ruth Wangondu MD PhD @Wang_Rwang]

@Wordslinger__ In the interests of safeguarding the public’s health, the veracity of these claims ought to be investigated by media and legislators, as a matter of priority. @mdjkitulu

[Satya Prakash Yadav @Satyayadav__]

Wow !
Simply wow - another chemotherapy free regimen for ph+ ALL

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

On day 84 - 100% CR and 89% MRD negative https://t.co/qHhEkXq3AU

[Harlan Krumholz @hmkyale]

NIH just made a drastic change to indirect cost rates, reducing the rate to 15%, a significant cut from the 60%+ some institutions charge. This will have a devastating effect on the nation’s medical research infrastructure. @ResearchAmerica @AAMC @YaleMed https://t.co/GQidBBR6C8

[Benlazar S M A @smbenlazar]

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia https://t.co/gc6owr1C5f #ALL #IKZF1 #IKAROS #leusm

[Benlazar S M A @smbenlazar]

IKZF1 in acute lymphoblastic leukemia: the rise before the fall? https://t.co/nBJQcZqGTR #leusm #ALL

[Ruth Wangondu MD PhD @Wang_Rwang]

On coping with the devastating loss of patients in cancer treatment "Caring words shaped by time and experience can help us process, cope, and continue on." The Holiday Card | JCO https://t.co/x53Mnt2dcR Heartfelt narrative and great advice by @doclauravater

[Satya Prakash Yadav @Satyayadav__]

Gene therapy for x-linked Adrenoleukodystrophy cured the disease but lead to development of leukemia in 7 children 👇

[Ruth Wangondu MD PhD @Wang_Rwang]

@Blood_Cancers @StJude @DrHKantarjian @StJudeResearch at #SOHO2024 earlier today, Dr. Pui delivered an excellent talk providing an overview of transformative research improving outcomes for children with acute lymphoblastic leukemia from St. Jude and other institutions #ChildhoodCancerAwarenessMonth

[Blood Cancers Today @Blood_Cancers]

LIVE from #SOHO2024: Ching-Hon Pui, MD, of @StJude, received the Emil J Freireich Distinguished Pioneer Award!

"Dr. Pui is admired by many of us and is a hero to many of us," said session chair @DrHKantarjian. "He is very well known for his work in childhood ALL."